We attribute this distinct separation of immunolabelling with BD sera from patient and healthy control sera to the in situ labelling of the NF-M epitope on the structurally intact neurofilaments, allowing for specific binding compared with the methods targeting denatured proteins such as Western blotting or ELISA. This evidence concerns the gene NEFM and Behcet disease.